救命治疗间的药物相互作用:雌化激素、抗逆转录病毒药与抗结核药的病例报告
一例30岁跨性别女性同时确诊HIV、梅毒和活动性结核,因利福平与比克替拉韦存在临床显著相互作用,抗逆转录病毒方案改为多替拉韦50mg每日两次联合替诺福韦二吡呋酯和恩曲他滨。患者自行使用含雌激素的雌化激素治疗,通过优化激素方案并密切监测雌二醇血药浓度来管理利福平与雌激素的相互作用,确保雌二醇维持在预期治疗范围内。该病例强调多病共存治疗最好由单一团队整合性别服务管理,以避免多次就诊和雌化激素治疗管理不当。
要点
- 利福平与比克替拉韦存在临床显著相互作用,需将抗逆转录病毒治疗调整为多替拉韦50mg每日两次。
- 利福平与雌激素存在药物相互作用,需优化激素治疗并密切监测雌二醇血药浓度以维持治疗范围。
- 多病共存治疗宜由单一团队整合性别服务管理,避免多次就诊和激素治疗管理不当。
核心结论
- 跨性别女性同时接受雌化激素、抗逆转录病毒和抗结核治疗时,需重视利福平相关的药物相互作用并个体化调整方案。
研究设计与样本
- 病例报告:一例30岁跨性别女性,确诊HIV、梅毒和活动性结核。
主要发现
- 患者启动比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨抗逆转录病毒治疗,并接受苄星青霉素G治疗梅毒。
- 结核ELIspot血检阳性,进一步检查证实胸部活动性结核伴纵隔受累,启动含利福平的四联抗结核治疗。
- 因利福平与比克替拉韦的临床显著相互作用,抗逆转录病毒治疗改为多替拉韦50mg每日两次联合替诺福韦二吡呋酯和恩曲他滨。
- 患者自行使用含雌激素的雌化激素治疗,通过优化激素方案并密切监测和滴定雌二醇血药浓度来管理利福平与雌激素的相互作用。
临床怎么用
- 对同时使用利福平和抗逆转录病毒药的跨性别患者,应评估相互作用并选择不受利福平显著影响的抗逆转录病毒方案。
- 对使用含雌激素雌化激素治疗且合用利福平的患者,应优化激素方案并密切监测雌二醇血药浓度以维持在预期治疗范围。
- 多病共存治疗宜由单一团队整合性别服务管理,以减少多次就诊和激素治疗管理不当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We here present a case providing valuable insights for clinicians who deliver care to patients identifying as transgender or nonbinary. A 30-year-old trans woman presented to sexual health services requesting a routine sexual health screen and was subsequently diagnosed with HIV and syphilis. She started antiretrovirals for HIV (bictegravir/tenoforvir alafenamide/emtricitabine) 12 days later and was treated with benzathine penicillin G. The patient also had a positive tuberculosis (TB) ELIspot blood test result and further investigations proved the presence of active TB in the chest with mediastinal involvement. She commenced treatment for TB with quadruple therapy, including rifampicin. Due to the clinically significant interaction between rifampicin and bictegravir, the patient's antiretroviral treatment was switched to dolutegravir 50 mg twice daily in combination with tenofovir disoproxil fumarate and emtricitabine. As the patient had transitioned from male to female and was self-medicating with oestrogen-containing feminizing hormone therapy, her hormonal treatment was optimized and blood levels of oestradiol were closely monitored and titrated to manage the drug-drug interaction between rifampicin and oestrogen to ensure the latter would be maintained within the expected therapeutic range. Our case report demonstrates the importance of combining treatment of multiple conditions under 1 team ideally integrated with gender services to prevent multiple attendances and mismanagement of feminizing hormone therapies.
引用
- Suchak T, Bracchi M, Mercer M, et al. A case report highlighting drug-drug interactions between 3 life-saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs. Br J Clin Pharmacol. 2024. PMID: 38599659. doi:10.1111/bcp.16064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。